Stock Analysis on Net

Zoetis Inc. (NYSE:ZTS)

$22.49

This company has been moved to the archive! The financial data has not been updated since May 2, 2024.

Economic Value Added (EVA)

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Economic Profit

Zoetis Inc., economic profit calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Net operating profit after taxes (NOPAT)1
Cost of capital2
Invested capital3
 
Economic profit4

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 NOPAT. See details »

2 Cost of capital. See details »

3 Invested capital. See details »

4 2023 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= × =


Net Operating Profit After Taxes (NOPAT)
The net operating profit after taxes exhibits an overall upward trend from 2019 to 2023, starting at $1,570 million and increasing to $2,410 million. There is a noticeable rise between 2020 and 2021, followed by a slight decline in 2022, and a significant recovery in 2023 surpassing previous years' figures.
Cost of Capital
The cost of capital remains relatively stable over the five-year period, with a slight upward trajectory from 12.77% in 2019 to 12.97% in 2023. The incremental increase is marginal, indicating consistent capital costs without major fluctuations.
Invested Capital
Invested capital shows variability throughout the period. It rises from $9,838 million in 2019 to a peak of $12,542 million in 2022, followed by a reduction to $11,550 million in 2023. This pattern suggests some asset base expansion until 2022, with a subsequent contraction or divestment in 2023.
Economic Profit
The economic profit demonstrates notable volatility. It increases from $313 million in 2019 to $632 million in 2021, dips to $334 million in 2022, then rises sharply to a high of $912 million in 2023. This variation reflects fluctuations in both profitability and capital efficiency, with 2023 marking the strongest performance in terms of creating value above the cost of capital.

Net Operating Profit after Taxes (NOPAT)

Zoetis Inc., NOPAT calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Net income attributable to Zoetis Inc.
Deferred income tax expense (benefit)1
Increase (decrease) in allowance for doubtful accounts2
Increase (decrease) in restructuring accruals3
Increase (decrease) in equity equivalents4
Interest expense, net of capitalized interest
Interest expense, operating lease liability5
Adjusted interest expense, net of capitalized interest
Tax benefit of interest expense, net of capitalized interest6
Adjusted interest expense, net of capitalized interest, after taxes7
Interest income
Investment income, before taxes
Tax expense (benefit) of investment income8
Investment income, after taxes9
Net income (loss) attributable to noncontrolling interest
Net operating profit after taxes (NOPAT)

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 Elimination of deferred tax expense. See details »

2 Addition of increase (decrease) in allowance for doubtful accounts.

3 Addition of increase (decrease) in restructuring accruals.

4 Addition of increase (decrease) in equity equivalents to net income attributable to Zoetis Inc..

5 2023 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =

6 2023 Calculation
Tax benefit of interest expense, net of capitalized interest = Adjusted interest expense, net of capitalized interest × Statutory income tax rate
= × 21.00% =

7 Addition of after taxes interest expense to net income attributable to Zoetis Inc..

8 2023 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= × 21.00% =

9 Elimination of after taxes investment income.


Net income attributable to Zoetis Inc.
The net income shows a consistent upward trend across the five-year period. Starting at 1,500 million USD in 2019, it increased each year, reaching 2,344 million USD by the end of 2023. The growth was steady, with notable acceleration between 2020 and 2021, and continuing to rise through 2023, indicating improving profitability over time.
Net operating profit after taxes (NOPAT)
NOPAT generally trended upwards from 1,570 million USD in 2019 to 2,410 million USD in 2023. There was a significant increase between 2019 and 2021, peaking at 2,131 million USD. A decline was observed in 2022, dropping to 1,958 million USD, before rebounding strongly in 2023 to the highest level in the period. This pattern suggests strong operational performance with some volatility in 2022, followed by recovery and growth.

Cash Operating Taxes

Zoetis Inc., cash operating taxes calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Provision for taxes on income
Less: Deferred income tax expense (benefit)
Add: Tax savings from interest expense, net of capitalized interest
Less: Tax imposed on investment income
Cash operating taxes

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).


Provision for Taxes on Income
The provision for taxes on income exhibits a consistent upward trend over the five-year period. Starting at $301 million in 2019, the amount increased each subsequent year, reaching $596 million in 2023. The growth appears steady, with noticeable jumps especially between 2020 and 2021, and continuing through 2022 and 2023. This indicates increasing tax liabilities or higher taxable income over time.
Cash Operating Taxes
Cash operating taxes generally increased from 2019 to 2022, starting at $422 million and peaking at $867 million in 2022. However, there is a significant decline observed in 2023, dropping to $687 million. While the overall trend is upward through most years, the decrease in the last year suggests changes in tax payment timing, effective tax rates, or operational adjustments impacting cash taxes paid.
Comparative Insights
Although both provisions for taxes on income and cash operating taxes increased overall, the divergence in 2023 is noteworthy. The provision continues to rise, whereas cash taxes paid decline, which may signal temporary timing differences or more efficient tax planning. The increasing provision paired with fluctuating cash taxes suggests that the accrual for taxes is rising in anticipation of income growth despite a recent drop in cash outflows for taxes.

Invested Capital

Zoetis Inc., invested capital calculation (financing approach)

US$ in millions

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Short-term borrowings
Current portion of long-term debt
Finance lease liabilities, current
Long-term debt, net of discount and issuance costs, excluding current portion
Finance lease liabilities, noncurrent
Operating lease liability1
Total reported debt & leases
Total Zoetis Inc. equity
Net deferred tax (assets) liabilities2
Allowance for doubtful accounts3
Restructuring accruals4
Equity equivalents5
Accumulated other comprehensive (income) loss, net of tax6
Equity attributable to noncontrolling interests
Adjusted total Zoetis Inc. equity
Construction-in-progress7
Available-for-sale debt securities8
Invested capital

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 Addition of capitalized operating leases.

2 Elimination of deferred taxes from assets and liabilities. See details »

3 Addition of allowance for doubtful accounts receivable.

4 Addition of restructuring accruals.

5 Addition of equity equivalents to total Zoetis Inc. equity.

6 Removal of accumulated other comprehensive income.

7 Subtraction of construction-in-progress.

8 Subtraction of available-for-sale debt securities.


Total reported debt & leases
The total reported debt and lease obligations exhibited some fluctuation over the five-year period. Initially, the debt increased from $6,646 million in 2019 to $7,402 million in 2020. This was followed by a decrease to $6,784 million in 2021. Subsequently, there was a noticeable rise to the peak value of $8,133 million in 2022, before dropping again to $6,812 million in 2023. Overall, the pattern shows volatility with a tendency to revert toward levels close to those observed at the beginning of the period.
Total Zoetis Inc. equity
The equity of the company demonstrated a generally upward trend throughout the period. Starting at $2,708 million in 2019, equity increased steadily, reaching $3,769 million in 2020 and continuing to $4,543 million in 2021. There was a slight decline in 2022 to $4,405 million, but equity rebounded to its highest value of $4,997 million by 2023. This upward trajectory indicates strengthening shareholder value over time despite the minor dip in 2022.
Invested capital
Invested capital rose consistently from $9,838 million in 2019 to $11,557 million in 2020. It then experienced marginal growth to $11,612 million in 2021, followed by a more pronounced increase to $12,542 million in 2022. In 2023, invested capital decreased to $11,550 million, marking a reversal after several years of growth. Overall, the data points to an expanding investment base, with some retrenchment in the latest year.

Cost of Capital

Zoetis Inc., cost of capital calculations

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt and finance lease liabilities3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2023-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt and finance lease liabilities. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt and finance lease liabilities3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2022-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt and finance lease liabilities. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt and finance lease liabilities3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2021-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt and finance lease liabilities. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt and finance lease liabilities3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2020-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt and finance lease liabilities. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt and finance lease liabilities3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2019-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt and finance lease liabilities. See details »

4 Operating lease liability. See details »


Economic Spread Ratio

Zoetis Inc., economic spread ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in millions)
Economic profit1
Invested capital2
Performance Ratio
Economic spread ratio3
Benchmarks
Economic Spread Ratio, Competitors4
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 Economic profit. See details »

2 Invested capital. See details »

3 2023 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =

4 Click competitor name to see calculations.


Economic Profit
The economic profit exhibited fluctuations over the observed periods, starting at 313 million USD in 2019, decreasing to 256 million USD in 2020, then surging to 632 million USD in 2021. It declined again to 334 million USD in 2022 before reaching the highest value of 912 million USD in 2023. This pattern suggests variability in profitability, with a notable improvement in the latest year.
Invested Capital
Invested capital generally increased from 9,838 million USD in 2019 to 12,542 million USD in 2022, indicating a growth in the capital base. However, there was a decrease to 11,550 million USD in 2023. The expansion from 2019 to 2022 may reflect strategic investment or asset accumulation, while the reduction in 2023 might imply divestment or capital efficiency measures.
Economic Spread Ratio
The economic spread ratio shows variability but trends upward overall. It started at 3.18% in 2019, fell to 2.22% in 2020, significantly increased to 5.44% in 2021, dropped to 2.66% in 2022, and peaked at 7.9% in 2023. This ratio indicates the return above the cost of capital and the marked rise in 2023 suggests a substantial improvement in the company's value creation relative to invested capital.
Summary of Trends
The company’s financial performance reveals cyclical fluctuations in economic profit and economic spread ratio over the five-year period. Despite some drops in 2020 and 2022, there is an overall positive trajectory with 2023 marking the highest figures in both economic profit and economic spread ratio. The invested capital increased up to 2022 but decreased in the final period, which may reflect shifts in capital management strategy. The improvement in economic spread ratio alongside the highest economic profit in 2023 suggests enhanced profitability and efficient use of invested capital in the most recent year.

Economic Profit Margin

Zoetis Inc., economic profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in millions)
Economic profit1
Revenue
Performance Ratio
Economic profit margin2
Benchmarks
Economic Profit Margin, Competitors3
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 Economic profit. See details »

2 2023 Calculation
Economic profit margin = 100 × Economic profit ÷ Revenue
= 100 × ÷ =

3 Click competitor name to see calculations.


The financial data over the five-year period indicate notable fluctuations and growth in key performance metrics.

Revenue
There is a consistent upward trend in revenue from 2019 to 2023. Revenue increased from 6,260 million US dollars in 2019 to 8,544 million US dollars in 2023, indicating steady growth in the company's sales or service income over the period.
Economic Profit
The economic profit experienced more volatility compared to revenue. It decreased from 313 million US dollars in 2019 to 256 million in 2020, then sharply increased to 632 million in 2021. It declined again in 2022 to 334 million, followed by a significant rise to 912 million in 2023. This pattern suggests fluctuating profitability, possibly influenced by changes in cost management, operating efficiency, or capital costs.
Economic Profit Margin
The economic profit margin, representing economic profit as a percentage of revenue, mirrors the volatility seen in economic profit. Starting at 5% in 2019, it declined to 3.84% in 2020, peaked at 8.13% in 2021, decreased to 4.13% in 2022, and then rose sharply to 10.67% in 2023. This indicates fluctuations in profitability relative to revenue, with a strong improvement in margin in the final year, suggesting enhanced economic value generated per revenue dollar.

Overall, while revenue growth is steady and positive, economic profit and economic profit margin show considerable variability, which may reflect changes in operational efficiency, cost structure, or external economic factors impacting the company's ability to generate profit beyond its cost of capital.